Adult including elderly Acute attacks 1 unit-dose vial. Severe cases May require 2nd unit-dose vial to be administered. Maintenance: 1 unit-dose vial tds or qds.
Immediate hypersensitivity reactions. Discontinue use if paradoxical bronchospasm occurs. Patients predisposed to glaucoma; insufficiently controlled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, phaeochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction; underlying severe heart disease eg, ischaemic heart disease, arrhythmia or severe heart failure; hypokalaemia; cystic fibrosis; acute, rapidly worsening dyspnoea. Positive doping test result. Avoid contact w/ eyes. Not to be mixed w/ other drugs in same nebuliser. May affect ability to drive & use machines. Hepatic or renal insufficiency. Pregnancy & lactation. Not to be used in childn.
R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.